Also known as: Alfuzosin hydrochloride
Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
Alfuzosin is the active ingredient of these drugs:
Poland
Poland
Cyprus Hong Kong
Poland
South Africa
Poland
Poland
Spain
United Kingdom
Poland
Italy
United Kingdom
Hong Kong Tunisia
Italy
Italy
Singapore
South Africa
Spain
France
Tunisia
Germany United States
United Kingdom
Hong Kong
Tunisia
Ireland
Australia Austria Brazil Canada Cyprus
United Kingdom